Ayman Amin

Dr Ayman Amin is a pharmacy-trained scientist with an MSc in Nanoscience and a PhD in Materials Science, bringing substantial postdoctoral and research-scientist experience spanning nanomaterials, electrochemistry, and analytical method development for biomedical and pharmaceutical applications. His has authored 25 research articles and six patents/patent applications, and has a strong record of research leadership in competitive, industry-backed programs (with budgets ranging from ~US$150k to ~US$725k).

His current work is centered on computational biomedical informatics, developing and translating AI/deep learning methods across biosignals (EEG and ECG), medical records, and medical imaging (CT/MRI), as well as digital pathology. He collaborates closely with neurology, cardiology, pathology, and other clinical departments to enable clinically useful decision-support and analytics. He is the recipient of multiple awards for Excellence in Publications and Best Presenter.

Biomedical signal analytics

Clinical data science

Translational biomedical informatics

Electrochemistry & electroanalytical method development

Nanomaterials & energy-storage materials

Pharmaceutical sciences

Dr Amin worked in pharmaceutical quality control and analytical method development in Egypt with Medizen Pharmaceutical Industries (2009‐2010) and nanotechnology research at the Centre for Nanotechnology, Nile University (2010‐2012). Between 2012 and 2021, he held appointments in Singapore at A*STAR, alongside PhD training at Nanyang Technological University. His work was focused on nanomaterials, electrochemistry, and energy-storage technologies, and held a strong record of publications, patents and patent applications, and funded research leadership.

He then held a postdoctoral role at the University of Sharjah (RISE, 2022–2024), developing electrochemical sensors and biomedical and pharmaceutical analytical methods. He has since joined Innovation & Research at KFSHRC in his current roles as Adjunct Scientist and industry consulting, with projects centred on AI and deep learning for multimodal clinical data, biosignals, imaging and medical records across clinical domains such as neurology, cardiology and pathology.